Login to Your Account



Intercell Plunges on Phase III Miss; Restructuring to Come

By Cormac Sheridan


Wednesday, December 15, 2010
Shares in Intercell AG plummeted 40 percent Monday on news that its patch-based vaccine for traveler's diarrhea failed to demonstrate efficacy in two studies, a Phase III trial in Central America and a Phase II pilot study in India. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription